Yes, but not the way cleanses and detox teas imply. Your body already cleans your blood continuously through the liver, kidneys, and spleen, processing roughly 1,500 liters of blood daily. Medical blood cleaning exists too, but it requires machines, catheters, and clinical supervision, and it treats specific diagnosed conditions rather than general toxicity.
That distinction matters because the phrase "clean your blood" spans three very different things. There is the physiological filtration your organs perform around the clock. There is extracorporeal therapy, in which a machine removes blood, filters or replaces part of it, and returns it to your body. And there is the commercial detox market, which borrows the language of the first two without their evidence. This explainer separates them, quantifies what each actually accomplishes, and flags where the claims outrun the data.
The kidney as a two-stage filtration system
Each kidney contains about one million nephrons, and each nephron begins with a glomerulus, a tangled capillary tuft that filters blood under pressure. The glomerular filtration rate in a healthy adult runs about 125 milliliters per minute, roughly 180 liters per day. Since a typical adult holds about 5 liters of blood, that means your entire blood volume passes through the kidneys' filters dozens of times daily.
The filtration itself is size- and charge-selective. The glomerular barrier holds back cells and most large proteins while letting water, salts, glucose, and small waste molecules through. What passes enters the tubule, where the kidney reabsorbs almost everything useful. Roughly 99 percent of the filtered water returns to the blood, along with nearly all filtered glucose and amino acids. What remains, about 1 to 2 liters, leaves as urine.
The liver runs a parallel operation. It converts ammonia, a byproduct of protein breakdown, into urea, which the kidneys then excrete. It also conjugates bilirubin and many drugs into water-soluble forms that filtration can remove. The spleen contributes by clearing aged red blood cells and some pathogens.
The counterintuitive part: your blood is never "clean" in a binary sense. It always contains urea, creatinine, and metabolic waste at low concentrations. Health is a matter of keeping those concentrations within narrow ranges, not eliminating them. A blood urea nitrogen level of 7 to 20 milligrams per deciliter is normal; zero would be abnormal.
How machines replicate kidney work
Hemodialysis does mechanically what nephrons do biologically. Blood flows from a surgically created vascular access through tubing into a dialyzer, a cylinder holding thousands of hollow fibers with semipermeable walls. Dialysate, a fluid matched to blood's electrolyte composition, flows on the outside of the fibers. Small molecules diffuse across the membrane down their concentration gradients, clearing urea and other wastes while electrolytes equilibrate.
A standard session runs about 4 hours, three times weekly, and processes 200 to 300 liters of blood. That sounds impressive until you compare it with the native kidney's 180 liters per day, which is why dialysis is a partial replacement rather than a cure. Middle-molecule clearance is imperfect, and fluid removal must be paced to avoid dangerous blood pressure drops.
Plasma exchange works differently. A machine separates plasma from blood cells by centrifugation or membrane filtration, discards the plasma, and returns the cells suspended in replacement fluid, typically albumin or donor plasma. A single session exchanges one to one and a half plasma volumes, roughly 3 to 4 liters in an adult. This removes circulating antibodies and large proteins that diffusion-based dialysis cannot clear, which is why it treats conditions like Guillain-Barré syndrome and thrombotic thrombocytopenic purpura.
A newer category, hemoperfusion and sorbent-based devices, passes blood over adsorbent materials such as activated carbon or resins. These bind specific molecules directly rather than relying on gradients. Several such devices hold regulatory clearance for limited indications, though evidence for broad use remains thin.
What dialysis achieves, by the numbers
Dialysis dosing is measured by Kt/V, a dimensionless ratio of clearance multiplied by time divided by urea distribution volume. The standard target for thrice-weekly hemodialysis is a single-pool Kt/V of at least 1.2. Below that threshold, mortality risk rises measurably.
The scale of the underlying problem is large. According to the CDC, more than 35 million American adults have chronic kidney disease, and most do not know it. Roughly 1 in 7 adults carries the diagnosis. When kidney function falls below about 15 percent of normal, termed kidney failure, dialysis or transplant becomes necessary.
Survival on dialysis is sobering. Five-year survival for patients starting dialysis in the United States sits near 40 percent, though this varies widely with age and comorbidities. That figure reflects the severity of underlying disease, not a failure of the therapy, but it undercuts any framing of dialysis as a routine tune-up.
Cost runs high. In the United States, Medicare spends more than USD 100 billion annually on patients with kidney failure, and per-patient dialysis costs commonly exceed USD 90,000 per year before accounting for hospitalizations. These figures explain why insurers scrutinize indications closely.
The professional caveat: more dialysis is not automatically better. Trials of more intensive schedules have generally failed to show survival benefit and sometimes increased vascular access complications. Adequacy targets are floors, not goals to exceed indefinitely.
Where blood cleaning becomes legitimate medicine
Plasma exchange carries category I evidence, the strongest tier, for a handful of conditions. These include Guillain-Barré syndrome, myasthenia gravis crisis, thrombotic thrombocytopenic purpura, and antibody-mediated rejection in kidney transplant. In these settings, removing pathogenic antibodies or abnormally large von Willebrand factor multimers produces measurable clinical improvement.
Dialysis indications are similarly specific. It treats uremia, dangerous hyperkalemia, fluid overload refractory to diuretics, and certain poisonings with dialyzable toxins such as lithium or methanol. Each indication has defined thresholds, and clinicians apply them individually rather than by blanket rule.
Some emerging applications remain investigational. Extracorporeal blood purification has been studied for sepsis and severe COVID-19, but major trials have largely failed to demonstrate mortality benefit. The FDA has issued clearances for specific devices in specific contexts, but clearance does not equal proven efficacy for every use.
The edge cases matter because they expose the gap between mechanism and outcome. A therapy can remove a target molecule and still fail to help, if the molecule was not driving the disease or if removal happens too late. This is why blood purification trials so often disappoint.
Red flags in the blood-cleansing marketplace
Commercial "blood cleansing" claims range from harmless to dangerous. Watch for these patterns.
Products promising to remove "toxins" without naming them, since an unnamed target cannot be measured or verified. Oral chelation supplements marketed for heavy metal removal in people without diagnosed exposure, which have caused deaths from hypocalcemia. Ozone therapy delivered by blood withdrawal and reinfusion, which lacks FDA approval and has caused air embolism and infection. Ultraviolet blood irradiation offered as a treatment for infections or cancer, which has no supporting trial evidence. Dialysis-style services advertised directly to consumers for fatigue or "anti-aging," since vascular access itself carries infection and clotting risks.
The regulatory boundary is worth stating plainly. The FDA has approved specific devices for specific indications. It has not approved "detox" as an indication for any blood purification device, and clinics that market beyond cleared uses are operating outside their authorization.
Comparison of blood-cleaning approaches
| Approach | What it removes | Evidence level | Typical setting | Main risk |
|---|---|---|---|---|
| Native kidney filtration | Urea, creatinine, electrolytes, water | Established physiology | Always active | None (normal function) |
| Hemodialysis | Small solutes, fluid | Strong for kidney failure | Outpatient, 3x weekly | Access infection, hypotension |
| Plasma exchange | Antibodies, large proteins | Strong for select diseases | Hospital | Bleeding, allergic reaction |
| Hemoperfusion | Specific bound molecules | Limited, indication-specific | Hospital | Clotting, electrolyte shifts |
| Oral chelation | Heavy metals, if present | Strong only for diagnosed toxicity | Prescribed | Hypocalcemia, kidney injury |
| Commercial detox products | Unspecified "toxins" | None | Retail | Delays real care, product harm |
Timeline: what happens during a single dialysis session
| Time | Event | What is happening |
|---|---|---|
| 0 min | Access check | Needles placed, blood flow confirmed |
| 5 min | Ramp-up | Blood flow and dialysate flow increase gradually |
| 30 min | Steady state | Urea clearance peaks, electrolytes shift |
| 2 hours | Midpoint | Largest volume of waste removed |
| 3 hours | Late phase | Fluid removal continues, blood pressure watched |
| 4 hours | Disconnection | Access held for bleeding, weight recorded |
The pattern explains a common clinical observation. Patients often feel worst in the hours after dialysis, not during it, because electrolyte and fluid shifts continue as compartments re-equilibrate. "Washed out" is a real physiological state, not a metaphor.
Practical actions that genuinely support blood filtration
If the goal is keeping your blood's composition in healthy ranges, the levers are unglamorous but measurable.
First, know your kidney numbers. A basic metabolic panel reports estimated glomerular filtration rate, and a urine albumin-to-creatinine ratio detects early damage. An eGFR below 60 for three months defines chronic kidney disease. An albumin-to-creatinine ratio above 30 milligrams per gram signals kidney damage even when eGFR is normal.
Second, control blood pressure. Hypertension is the second leading cause of kidney failure after diabetes. Targets generally sit below 130/80 millimeters of mercury for most adults with kidney disease, though individual targets vary.
Third, manage blood glucose if diabetic. An A1c near 7 percent slows progression of diabetic kidney disease in most patients, with individualization for age and comorbidities.
Fourth, avoid kidney insults. Nonsteroidal anti-inflammatory drugs taken regularly can reduce kidney blood flow. Contrast dye carries risk in impaired kidneys. Unregulated herbal supplements, particularly those containing aristolochic acid, cause progressive kidney injury.
Fifth, stay hydrated within reason. There is no evidence that extreme water intake "flushes toxins" beyond what kidneys already do, but chronic dehydration does concentrate urine and raise stone risk.
The threshold reconciliation deserves explicit statement, because sources differ. Kidney disease stages are defined by eGFR: stage 1 is 90 or above with damage markers, stage 2 is 60 to 89, stage 3a is 45 to 59, stage 3b is 30 to 44, stage 4 is 15 to 29, and stage 5 is below 15. Dialysis typically begins in stage 5 when symptoms or complications appear, not automatically at a specific number. Some guidelines use different albuminuria cutoffs, but the 30 and 300 milligrams per gram boundaries are the most widely applied.
The limits of what cleaning can accomplish
Blood purification cannot compensate for a lifestyle that keeps generating the problem. Dialysis patients who skip sessions accumulate potassium and fluid between treatments, and the resulting emergency department visits are common. Plasma exchange removes antibodies, but the immune system may produce more within days, which is why it is combined with immunosuppression rather than used alone.
Nor can any therapy remove a toxin it cannot reach. Molecules bound tightly to tissue, stored in fat, or sequestered inside cells clear slowly regardless of how efficient the extracorporeal circuit is. This is a core reason blood purification underperforms in sepsis: the injurious mediators are distributed throughout tissue, not concentrated in plasma.
Finally, the word "clean" obscures an important truth. Blood is supposed to contain waste products in transit. The measure of health is not purity but regulated concentration, maintained by organs that work continuously and without conscious effort. Anyone selling purity is selling a category error.
If you have symptoms suggesting kidney problems, such as swelling, fatigue, or changes in urination, the useful action is a blood and urine test ordered by a clinician, not a supplement. If you encounter a clinic offering blood cleaning for nonspecific complaints, ask which device, which indication, and which regulatory clearance. The answer will usually settle the question.